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Background/aim: We aimed to investigate the topical application of mitomycin-C (MMC) after the conventional tracheostomy in
a rabbit model.
Materials and methods: Twenty-four male New Zealand White rabbits were randomly divided among 3 equal groups (n: 8). Tracheostomies were performed on 16 subjects. Group 1 which served as a control for all tracheal measurements. After tracheostomy, we
applied sterile saline (group 2) or MMC at 0.8 mg/mL (group 3) around the tracheotomy site for 5 min. At the 3rd week after surgery,
all tracheas were subjected to morphometric and histopathological examinations, including tracheal lumen diameter (LD), number
of capillary vessels (CV), subepithelial tissue thickness (SETT), fibroblasts, and inflammatory cells (IC).
Results: There was a statistically significant difference between the two tracheostomy groups themselves and the control group for LD (p
= 0.035), CV (p = 0.006), SETT, fibroblasts, and IC (p < 0.001). Histopathological analysis showed the decreased LD, CV, SETT, IC, and
fibroblasts compared to MMC with tracheostomy groups. MMC was more effective than saline for LD, CV, SETT, IC, and fibroblasts.
Conclusion: Wound healing modulation may prevent scar formation. Fibrosis decreased following tracheostomy in the group treated
with MMC. Fibroblasts appear to be key cells mediating these effects.
Key words: Tracheostomy, tracheal epithelia, rabbits, mitomycin-C (MMC)

1. Introduction
Tracheostomy, most commonly carried out in intensive
care settings, is a life-saving tool for modern physicians
[1,2]. In spite of its broad range of indications, there are
only two absolute contraindications: significant skin or
soft tissue infections and conditions leading to distorted
anatomy. Tracheostomy is indicated for ventilator-dependent patients to facilitate ventilator weaning. Additionally, it allows convenient access for pulmonary toileting, reduces the need for sedatives, promotes patient comfort, reduces the risk of long-term sequelae of endotracheal
tube placement, and potentiates intensive care unit (ICU)
discharge [3].
Unfortunately, tracheostomy is also associated with
appreciable morbidity, with reported complication rates
of 8%–45% [3,4]. Tracheostomy-related complications
include early and late complications. One of the most
devastating late complications is benign tracheal steno-

sis, which can occur following prolonged intubation and
tracheostomy.
Mitomycin-C (MMC) is an antitumor and antimitotic
drug that is derived from Streptomyces caespitosus. It has
an antineoplastic and angiogenesis properties that break
DNA cross-linking like alkylating agents. At higher
concentrations, it inhibits protein and RNA synthesis
[5]. MMC inhibits in vitro fibroblast proliferation, causes
apoptosis in fibroblasts, and prevents the formation of
scars and fibrosis in humans. Although MMC can be
toxic when administered systemically, t he topical application prevents systemic toxicity [6]. Its effects have been
tested during surgical treatments for pterygium, upper
urinary tract urothelial tumors, endoscopic sinus procedures, maxillary antrostomy, and dacryocystorhinostomy
[7]. We aimed to investigate the effects associated with
topical application of MMC after conventional tracheostomy in a rabbit model.
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2. Materials and methods
Twenty-four male, 24-week-old New Zealand White rabbits were used for this study and were randomly divided
among 3 groups. All animals received humane care and
were used in compliance with standards established by the
European Convention for Animal Care and Use of Laboratory Animals. The rabbits were fed a standard pelleted
diet and were allowed to access tap water ad libitum. The
animals were housed in standard individual cages on a 12-h
light/dark cycle at room temperature in a humidity-controlled environment. The local Animal Ethical Committee approved all study-related procedures. This study was
approved and funded by the School of Medicine Animal
Care and Investigational Committee at our institution.
2.1. Groups
Each of the three equal groups contained eight rabbits.
Group 1 served as a control for tracheal measurements.
After the tracheostomy, we applied either sterile saline
(group 2) or MMC at 0.8 mg/mL (group 3) (Mitomycin-C
Kyowa 10 mg/flk, Kyowa Hakko Kogyo Ltd. Tokyo, Japan)
for 5 min.
2.2. Anesthesia
General anesthesia was induced with ketamine HCl (Ketanest, Pfizer Pharma GmbH, Karlsruhe, Germany), 15–
20 mg/kg i.v. or 20–25 mg/kg i.m. moreover, maintained
with xylazine (alfazyne 2%; Alfasan International. BV,
Woerden, Netherlands) 0.5–1 mg/kg i.v. or 1–2 mg/
kg i.m. If needed, standard doses of ketamine HCl or
xylazine were repeated upon the emergence of reflex responses (pedal reflex, palpebral, and corneal reflexes) to
maintain a constant anesthesia depth. Body temperature
was monitored by inserting a heat probe into the ECG and
rectum by the aid of needle electrodes. Heating lamps were
used to keep the animals at 37 ± 5 °C body temperature
during the surgical preparation and working periods. The
mean anesthesia time was 12–15 min for each rabbit.
No animals were treated with any local or systemic antibiotics.
2.3. Operative technique
Under general anesthesia, all rabbits were placed in the
supine position on the operating table while breathing
spontaneously. Their necks were shaved and cleaned
with povidone-iodine solution. A vertical midline cervical incision performed over the larynx after infiltrating
with 1% lidocaine and with 1:100000 epinephrine (Jetokain Simplex ampule; Adeka Pharmaceutical Company,
İstanbul, Turkey). The strap muscles were divided along the
median raphe to allow exposure of the larynx, cricoid, and
superior trachea. A horizontal incision was made under
the cricoid, at the level of 2nd or third 3rd rings (Figure 1).
A sterile tube from the intubation set was introduced into
the trachea and fixed to the strap muscle (Figure 2). Then,
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the skin was sutured with 4/0 silk suture. Classic tracheostomy was performed on 16 rabbits. Group 1 served as
a control for tracheal measurements. After tracheostomy,
group 2 rabbits had sterile saline applied topically, with
cotton pledgets, around the tracheostomy tube site for 5
min. For group 3, MMC (0.8 mg/mL) was applied topically,
using cotton pledgets, for 5 min.
2.4. Postoperative care and follow-up
Pain control in animals was provided with tradomol HCl
(contramal, 100 mg, 2 mL, Abdi Ibrahim Ltd., Istanbul,
Turkey) 1–2 mg/kg/day i.m. for 5 days during the postoperative period. The animals were followed-up for 3 weeks
after surgery. All animals were painlessly euthanized with

Figure 1. A horizontal incision was made under the cricoid at the
level of trachea.

Figure 2. The tube obtained in sterile conditions from intubation
set was introduced into the trachea and the tube fixed to the
strap muscle.
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a lethal intravenous (IV) dose of nonbarbiturate anesthetic
(ketamine/xylazine), according to instructions established
by the latest report of the American Veterinary Medical
Association (AVMA) Panel on Euthanasia. The anesthetic
dose used was three times that necessary for euthanasia
[8].
2.5. Pathological evaluation
The larynx and trachea that were acquired from each subject were immediately fixed with 10% buffered formaldehyde. The tracheotomy sites of each specimen were cut
transversely into 3 mm sections (5 sections per material).
Samples were processed according to the autotechnician
process, embedded in paraffin wax, and cut into 5 μm sections by a rotary microtome. Tissues were mounted on
slides and stained with hematoxylen and eosin (H&E) and
Masson’s trichrome. These tissues were examined under
a Nikon Eclipse E400 light microscope (Nikon Corporation. Minato Ku, Tokyo Japan). The slides were photo-

graphed using Nikon Coolpix 5000 photographic attachment (Nikon Corporation). Photographs of the Nikon
micrometer microscope slides (Nikon Stage Micrometer
MBM11100) were also taken during the procedure. All
photographs were then transferred to a computer and
subjected to morphometric examination. The length was
calibrated using a photograph of the Nikon micrometer microscope slide, which was taken under the same
magnification. Tracheal lumen diameters (LD) (Figure 3)
and subepithelial tissue thickness (SETT) (Figure 4) were
measured with the Clemex Vision Lite 3.5 image analysis
program (Clemex Technologies Inc. Longueuil, Quebec,
Canada). We designated 0.25 mm square areas using the
Clemex Vision Lite 3.5 image analysis system. Fibroblasts,
inflammatory cells (IC), and capillary vessels (CV) were
marked and automatically counted with the same image
analysis system. The H&E sections were used to analyze
IC. Other measurements were performed on Masson’s

Figure 3. Tracheal lumen diameter is measured at the 20-fold magnified area in tissue samples by Clemex Vision Lite 3.5 image analysis
system. The measurement is made on the narrowest line in the midline.

859

ÇALIK et al. / Turk J Med Sci

Figure 4. Subepithelial tissue thickness is measured at the 20-fold magnified area in tissue samples by the same image analysis system.
The thickness is measured in a few places during the measurement, and the average is calculated automatically by the Clemex Vision
Lite 3.5 image analysis system.

trichrome stained sections. Damaged cells were excluded
from the evaluation. All slides were examined by the same
pathologist, in a blinded fashion.
2.6. Statistical analysis
Data was assessed using the SPSS v.18.0 portable for Windows programme (SPSS Inc, Chicago, IL, USA). Data noted at 3 weeks posttracheostomy are expressed as medians
and interquartile ranges. Between-group comparisons
were made by the Kruskal–Wallis Test. The Mann–Whitney U-test was used to compare the control and saline/
MMC groups. A p-value < 0.05 was used to indicate a significant difference.
3. Result
Regardless of the cause of death, dead animals were replaced with new ones. Twenty-four rabbits were included
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in our experiment, and all lived to the end of the 3 weeks.
There were no instances of skin reaction, wound infections, or bleeding around the surgical sites during the
perioperative period. No local complications attributable to
MMC were encountered.
There was a statistically significant difference (p ˂
0.035) between the groups in LD. In group 1, LD was
3198.8 (3027.3–3926.9). A maximum diameter loss of
2530.3 (1415.3–2897.5) was detected in group 2, and a loss
of 3243.3 (2148.6–3771.9) was found in group 3. Because
of the lack of between-group differences in LD between the
MMC and control groups, it appears that MMC did not
prevent lumen diameter loss.
Differences in SETT were statistically significant (p ˂
0.006). In the control group, SETT was 168.3 (94.3–281.1).
The highest increase in SETT was in group 2, with 516.1
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(327.3–741.1). This was followed by group 3, with 298.9
(243.9366). Compared with the control group, SETT was
increased by 3-fold in group 2 and 1.7-fold in group 3.
Between-group differences in IC were statistically significant (p ˂ 0.001). We detected 10 (6.5–16) ICs in the
control group. The highest increase in IC was in g roup
2, with 229.5 (48.5–454), followed by group 3, with 34
(30.5–39). Compared with the control group, there was a
23-fold increase in IC for group 2, and a 3.4-fold increase
in IC for group 3.
There were statistically significant between-group
differences (p ˂ 0.001) in the CV. In the control group,
we detected 4 (2–6) CVs. The highest increase in CV was
group 2, with 19 (15– 29.5), followed by group 3, with 8
(6–9). Compared with the control group, CV was increased
five-fold in group 2 and two-fold in group 3.
There were statistically significant between-group
differences (p ˂ 0.001) in the number of fibroblasts. In
the control group, we detected 5 (3.5–8) fibroblasts. The
highest increase in fibroblasts was in group 2, with 30.5
(21–36), followed by group 3, with 10 (8.5–14) fibroblasts. Compared with the control group, fibroblasts were
increased by six times for group 2, and 2.4 times for group
3.
There was a statistically significant difference between
IC, CV, and fibroblasts in group 1 (control) and group 2
(tracheostomy + sterile saline). P-values were 0.007, 0,
042, and 0.037, respectively. LD (p = 0.730) and STT (p
= 0.068) differences in the same groups could not be detected. LD, STT, IC, CV, and fibroblasts were significantly
different in group 1 (control) and group 3 (tracheostomy
MMC). P-values were 0.009, 0.024, 0.013, 0.014, and 0.023,
respectively. In group 1 (tracheostomy sterile saline) and
in group 3 (tracheostomy MMC), there was a statistically
significant difference between IC, CV, and fibroblasts, but
not LD and STT. P-values are 0.111, 0.111, 0.006, 0.006,
and 0.02, respectively.
All the above values are listed in Table. MMC was more
effective than saline for LD, SETT, IC, CV, and fibroblasts.

4. Discussion
Surgery and trauma unavoidably cause scarring, particularly in circular organs. These processes including tracheostomy can incite complications, including the formation of fibrotic tissue such as stenosis [6]. Tracheal stenosis (TS) is a significant reduction in the tracheal lumen,
life-threatening and largely preventable. Today, MMC is
used successfully in various surgical fields, including ophthalmology, otorhinolaryngology, and urology to prevent
scar formation. As shown in our study; fibroblasts are
one of the critical cells in scar formation, but they are not
unique. MMC can be used to prevent the development of
antiproliferative activity and stenosis in a limited dose and
time [6,9].
TS is a potentially life-threatening condition, it lowers
the quality of life, and, for clinicians it is the most challenging complication encountered in airway surgery [10].
Thankfully, clinically significant stenosis is very rare and
occurs in less than 2% of patients, however, its worldwide incidence remains unknown [11]. While several
treatments have been used for tracheal stenosis, these
tend to fail due to the new scar formation and restenosis through either the persistence of the chronic inflammatory processes that caused the initial stenosis or as an
iatrogenic result of surgical intervention [12]. Because
of the MMC’s effect on fibroblast proliferation in TS,
many in vitro and in vivo studies are available. However,
Wang et al. have not recommended its use because of
increasing anastomosis complications after resection. In
another study, Gangar et al. used MMC for 16 years, but
it has not been proven to be useful. The result is that the
utility of MMC remains hypothetical and its future role
is unclear [13]. Wang et al. evaluated 263 patients with
idiopathic subglottic stenosis, over a period of 42 years.
MMC was administered to 27 patients (11.4%) in the form
of endobronchial injection without the mention of dose
and duration of administration, and steroids were given
to 12 patients (5%) over 40 years. Importantly, steroids can lead to anastomotic complications, as noted
in the literature [14]. Gangar et al. studied pediatric airway

Table. Comparison of experimental group parameters.

Tracheal lumen diameter*

Group 1
Group 2
Group 3
p- value
( control )
( tracheostomy + sterile saline) ( tracheostomy + MMC)
3198.8 (3027.3–3926.9) 2530.3 (1415.3–2897.5)
3243.3 (2148.6–3771.9) 0.035

Subepithelial tissue thickness* 168.3 (94.3–281.1)

516.1 (327.3–741.1)

298.9 (243.9–366)

0.006

Inflammatory cells**/***

10 (6.5–16)

229.5 (48.5–454)

34 (30.5–39)

<0.001

Capillary vessels **/***

4 (2–6)

19 (15–29.5)

8 (6–9)

<0.001

Fibroblasts**/***

5 (3.5–8)

30.5 (21–36)

10 (8.5–14)

<0.001

*μm; **μm/pixel; *** 0.25 mm2/ cell.
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diseases, and in a randomized, double-blind, placebo-controlled study, they applied 0.4 mg/mL MMC for 2 min in
24 patients. Their study was terminated and the treatment
considered invalid. In a similar study, 0.5 mg/mL topical
MMC was administered to 26 patients, either one or two
times, here, the double application was found to be more
beneficial. However, the authors attribute this to their use
in more serious and difficult situations [15].
MMC can be used topically in surgical wounds, areas
where excessive fibrosis formation can lead to functional
impairment. MMC solution-soaked cotton can be applied
to the operative area, with optimum control of the location and duration of application. Although the ideal application time and t h e dose of MMC are still matters of debate, MMC has been successfully used as an
adjunctive therapeutic agent to prevent excessive scarring
in various surgical fields including ophthalmology, otorhinolaryngology, and urology. Most human studies used
a topical dose of 2–10 mg/mL, which is due to its historic use in ophthalmological studies, and 0.1–0.4 mg/
mL, in animal studies. The application time varied from 2
to 5 min. We decided to use MMC for the longest period (5 min) reported in the literature, and at twice the
upper dose used in animal studies. We, however, agree
that humans can safely use and heal across a wider field
of less-sensitive tissues, over repeated doses, and in higher
concentrations [15]. In vitro, MMC inhibited proliferation
of human fibroblasts at 1.6 mg/mL. This effect of MMC increases with dose and, in animal models, in vivo cultures,
and airway it is limited to 3 weeks. On skin, it is limited
to 4 weeks [16]. Therefore, we limited our study period to
3 weeks.
Even though TS is a small research area, it can threaten
and lower quality of life. There are countless animal experiments and patient series in the literature that used MMC.
The studies affirming its usefulness are mostly retrospective and case presentation in nature. Low-doses and small
patient cohorts have rarely been used prospectively. According to our best knowledge, only one English-language
study examined SETT in response to topical application of
MMC. Our experimental study on this subject will, therefore, be the second.
Wang et al. applied MMC to 27 patients (11.5%) over
a 40-year research period. That is, less than one patient
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per year (0.675 patients per year); moreover, they did not
specify the dose or form of administration. The efficacy
of MMC is limited to 3 weeks, even in high doses, and has
no effect in low-dose, heterogeneous, and small patient cohorts.
We used MMC to prevent the formation of scar tissue.
In accordance with the literature there were statistically
significant differences between the tracheostomy and control groups for LD (p = 0.035), CV (p = 0.06), SETT, fibroblasts, and the number of lymphocytes (p < 0.001). We feel
these effects were due to t h e high dose used. In addition,
topical application prevented MMC from inciting localized complications.
This study has some limitations. Firstly, as an experimental animal study, our research results could differ if
human tissues are used, therefore, additional prospective
studies are needed.
Moreover, wound healing modulation may prevent
scar formation but additional studies are needed to prove
this. L a s t l y, fibroblasts are key cells, but t h e y a r e not
the only cells involved in these processes. Realistically, a
single dose of medication is likely insufficient for preventing scar formation. In the future, more powerful and
long-term derivatives of MMC and/or new drugs should
be studied since MMC is a medication that has a dose and
time restriction for antiproliferative activity on fibroblasts.
Acknowledgment
This study was approved and funded by the School of
Medicine Animal Care and Investigational Committee in
our institution.
Disclaimers
This case was presented as a poster presentation in the
American College of Chest Physicians (CHEST) Meetings October 24-28. Montréal, Québec, Canada; 2015;
and published as a supplement CHEST Journal October
2015; 148 (4_meeting abstracts): 300A-300A. doi: 10.1378/
chest.2281105.
Conflict of interest
The authors declared no conflict of interest.

ÇALIK et al. / Turk J Med Sci
References
1.

Cardone G, Lepe M. Tracheostomy: complications in fresh
postoperative and late postoperative settings. Clinical Pediatric Emergency Medicine 2010; 11 (2): 122-130. doi: 10.1016/j.
cpem.2010.04.001

9.

Lewis S, Earley M, Rosenfeld R, Silverman J. Systematic review
for surgical treatment of adult and adolescent laryngotracheal
stenosis. Laryngoscope 2017; 127 (1): 191-198. doi: 10.1002/
lary.26151

2.

Lissauer M.E. Benefit, timing, and technique of tracheostomy. Current Problems in Surgery 2013; 50 (10): 494-499. doi:
10.1067/j.cpsurg.2013.08.015

10.

3.

Tobler WD, Agarwal S. Tracheostomy current surgical therapy: expert consult. Cameron JL, Cameron AM (editors). 11th
ed. 1241. Philadelphia, PA, USA: Elsevier Saunders 2014.
p.1238.

Şen S, Meteoğlu I, Ogurlu M, Şen S, Derincegöz OO et al.
Topical heparin: a promising agent for the prevention of tracheal stenosis in airway surgery. Journal of Surgical Research
2009; 157 (1): 23-29. doi: 10.1016/j.jss.2009.01.028

11.

4.

Coyle MJ, Shrimpton A, Perkins C, Fasanmade A, Godden D.
First do no harm: should routine tracheostomy after oral and
maxillofacial oncological operations be abandoned? British
Journal of Oral and Maxillofacial Surgery 2012; 50 (8): 732-735.
doi: 10.1016/j.bjoms.2012.01.003

Herrak L, Ahid S, Abouqal R, Lescot B, Gharbi N. Tracheal stenosis after intubation and/or tracheostomy. Egyptian Journal
of Chest Diseases and Tuberculosis 2014; 63 (1): 233-237. doi:
10.1016/j.ejcdt.2013.10.015

12.

5.

Arbağ H, Avunduk MC, Özer B, Öztürk K, Ülkü CH. Increased expression of epidermal growth factor receptors
in the tracheal epithelia after topical mitomycin-C in rabbits. Auris Nasus Larynx 2005; 32: 65-70. doi: 10.1016/j.
anl.2004.11.011

Cincik H, Güngör A, Çakmak A, Ömeroğlu A, Poyrazoğlu E
et al. The effects of mitomycin C and 5-fluorouracil/triamcinolone on fibrosis/scar tissue formation secondary to subglottic
trauma (experimental study). American Journal of Otolaryngology 2005; 26: 45-50. doi: 10.1016/j.amjoto.2003.07.002

13.

6.

Veen EJD, Dikkers FG. Topical use of MMC in the upper
aerodigestive tract: a review on the side effects. European Archives of Oto-Rhino-Laryngology 2010; 267 (3): 327-334. doi:
10.1007/s00405-009-1151-0

Tsakiridis K, Darwiche K, Visouli AN, Zarogoulidis P, Machairiotis N et al. Management of complex benign post-tracheostomy tracheal stenosis with bronchoscopic insertion of silicon tracheal stents, in patients with failed or contraindicated
surgical reconstruction of trachea. Journal of Thoracic Disease
2012; 4 (1): 32-40. doi: 10.3978/j.issn.2072-1439. 2012.s002

14.

Fatimi SH, Qasim Raza M, Ghani A, Shah N, Ashfaq A.
Tracheal reconstruction for complex acute tracheal stenosis annals of medicine and surgery. Annals of Medicine and
Surgery (London) 2013; 4-2 (2): 57-59. doi: 10.1016/S20490801(13)70038-4

15.

Grillo HC. Stents and sense. Annals of Thoracic Surgery 2000;
70: 1142. doi: 10.1016/s0003-4975(00)01796-3

16.

Marel M, Pekarek Z, Spasova I, Pafko P, Schutzner J et al. Management of benign stenosis of the large airways in the university hospital in Prague, Czech Republic, in 1998-2003. Respiration 2005; 72 (6): 622-628. doi: 10.1159/000089578

7.

8.

Iñiguez-Cuadra R, San Martín Prieto J, Iñiguez-Cuadra M,
Zúñiga Erranz S, Jofré Pavez D et al. Effect of mitomycin in
the surgical treatment of tracheal stenosis. Archives of Otolaryngology – Head & Neck Surgery 2008; 134 (7): 709-714. doi:
10.1001/archotol.134.7.709
Leary S, Underwood W, Anthony R, Cartner S, Corey D et. al.
AVMA Guidelines for the Euthanasia of Animals: 2013 ed.
Schaumburg, IL, USA: American Veterinary Medical Association; 2013. p. 1102

863

